UPFRONT BRIEFING
Isomorphic Labs just raised $5B without naming a single molecule, a record private biotech round and the clearest sign yet that crossover money will still write cheques this size for an AI platform. Sellas, meanwhile, did it the old-fashioned way: a Phase 3 survival win in AML, followed within hours by a $150M offering.
In Washington, the White House pulled Heidi Overton’s FDA nomination on Tuesday evening, hours before today’s HELP committee vote, so the agency stays without a confirmed commissioner into another round of hearings. Jefferies London wraps Thursday, and Capricor’s deramiocel PDUFA lands Sunday.
TAPE ACTION

Biotech fell less than the market: XBI (0.4%) and NBI (0.7%) vs the S&P 500 (1.0%), with BBC (1.7%) weaker. XLV’s (1.4%) drop tracked managed care, where UnitedHealth (5.4%), Molina (5.1%) and Humana (3.9%) sold off after CMS’s Monday-night proposal to expand Medicare Advantage audits.
The S&P 500 closed at 7,340.53, a five-month low, and the Dow fell (1.6%) as software sold off: Salesforce (9.5%), Intuit (7.2%), ServiceNow (6.5%), IGV (3.3%). St. Louis Fed’s Musalem said up to four more hikes may be needed by spring, and the NAHB index fell to 25, a 14-year low. The 10Y slipped 2bp to 5.10% and the VIX rose 11% to 25.46. After the bell, Nvidia beat (revenue $115.84B vs $109.1B, Q4 guide ~$130B) and rose ~3% after hours.
THE BIG 3
1️⃣ — Isomorphic Labs raises record $5B Series C
Isomorphic Labs, Alphabet’s AI drug-design spinout, raised a $5B Series C co-led by Greenoaks and Sequoia Capital, with Alphabet and new investors including Andreessen Horowitz. It is the largest private biotech round on record, more than double its own $2.1B Series B in May.
Why it matters: $5B with no disclosed molecule and no trial running: Isomorphic has now raised $7.1B in six months, and this round alone beats the $3B Altos Labs debut that held the record since 2022. The money takes internal oncology and immunology programs into the clinic alongside partnered work for Lilly, Novartis and J&J, so the nearer-term read is deal leverage rather than data: a platform this well funded can demand bigger economics from pharma or keep assets in-house. Greenoaks and Sequoia paid up while the tech tape was punishing AI spend. The risk is plain. No AI-designed drug has been approved, Isomorphic has not named a candidate, and the valuation rests on preclinical claims and Demis Hassabis’ record.
Source: Fierce Biotech
More: BioPharma Dive; BioSpace
2️⃣ — White House withdraws Heidi Overton FDA nomination
The White House withdrew Heidi Overton’s nomination for FDA commissioner on Tuesday evening, hours before the Senate HELP committee’s scheduled Wednesday vote, after opposition from Senate Republicans and MAHA allies.
Why it matters: The withdrawal landed after Tuesday’s close, hours before a HELP vote where Republicans hold a one-seat majority and MAHA allies had lined up against her. The FDA has now gone roughly six months without a confirmed commissioner, with new CNPV vouchers stalled and CRL publication apparently paused (Big 3, 13 Nov). Reviews are still moving: Nelkarmi cleared ten days early on Tuesday, so the exposure is policy rather than PDUFA dates. Accelerated-approval posture, the voucher program and how hard reviewers lean on ex-US data after the ivonescimab letter all sit with acting leadership. A new nominee restarts hearings, which pushes a confirmed commissioner into 2027.
Source: STAT
More: Fierce Pharma; BioSpace
3️⃣ — Sellas vaccine wins Phase 3 survival in AML, then raises $150M
Sellas’ galinpepimut-S (GPS), a WT1-targeted cancer vaccine, met the overall survival primary endpoint of the pivotal Phase 3 REGAL trial. Patients were transplant-ineligible and in second or later remission with AML. HR 0.59 (two-sided p=0.035), median OS 24.0 vs 14.7 months on best available treatment, at the pre-specified 80 deaths. Side effects were mostly grade 1/2 injection-site reactions.
Why it matters: Maintenance for transplant-ineligible AML patients in second remission has almost nothing approved, so an OS win here is a real label. The statistics are thin, though: 80 deaths, a two-sided p=0.035 and secondary endpoints still being analysed leave the FDA room to probe control-arm choice and subgroup balance before an accelerated filing. STAT’s Adam Feuerstein, who predicted failure in September, wrote that he was wrong. Sellas launched a $150M offering through J.P. Morgan and TD Cowen the same day, off a $7.47 Monday close, so dilution is the near-term overhang. BLA timing is 1H27 after an FDA meeting. A WT1 vaccine win also gives off-the-shelf AML maintenance a reason for fresh BD interest.
Source: STAT
EVERYTHING ELSE THAT BROKE
Merck scrapped nemtabrutinib (MK-1026), the oral non-covalent BTK inhibitor from its ArQule buyout, across the whole Phase 3 BELLWAVE program. An independent DMC found its benefits may not outweigh the risks in BELLWAVE-011 in CLL/SLL. — Merck release
Kyntra Bio (formerly FibroGen) cut a mid-stage antibody-drug conjugate program from its pipeline. — Fierce Biotech
AriBio’s oral PDE5 inhibitor mirodenafil met its monotherapy goal in a global Phase 3 Alzheimer’s trial, with otherwise mixed results; Fosun Pharma holds an option to in-license it. — Fierce Biotech
GSK won accelerated FDA approval for Nelkarmi (neladalkib) in ALK-positive NSCLC after prior ALK TKIs, ten days ahead of its 27 Nov goal date. ORR was 49% after alectinib alone and 32% after two or more TKIs plus chemo (ALKOVE-1). It is the second approval from GSK’s $10.6B Nuvalent buyout. — GSK release
The FDA’s complete response letter for Summit/Akeso’s ivonescimab faulted the filing’s reliance on China-heavy data, not just the HARMONi survival miss. — Fierce Pharma
Beren won FDA approval for Lembaz (adrabetadex), the first medicine shown to improve survival in infantile-onset Niemann-Pick disease type C. — Endpoints
Novartis’ Cosentyx won FDA approval for an 11th indication as Novartis works to cushion its 2029 patent cliff. — Fierce Pharma
Biogen’s tau ASO diranersen widened its slowing of decline at two years in the Phase 2 CELIA study in early Alzheimer’s, with the 60 mg twice-yearly dose showing the largest effect (CTAD). — Endpoints
Inhibrx posted updated ozekibart data in relapsed/refractory Ewing sarcoma: 62.7% ORR and 86.3% DCR. — PR
DEAL FLOW
Track the Deals Shaping Biotech
Track M&A, licensing agreements, IPOs and venture financings. Explore deal values, key terms and transaction details in our regularly updated BioBucks trackers.
M&A / BD&L
Viatris completed its $36.50-per-share cash acquisition of Pacira BioSciences (Exparel, Zilretto) after a tender for ~66.5% of shares (announced 8 Oct). — Viatris release (8-K)
VC / PRIVATE FINANCINGS
Isomorphic Labs: $5B Series C, co-led by Greenoaks and Sequoia Capital, joined by Alphabet and Andreessen Horowitz. AI drug design, preclinical. — BioSpace
Marrow Therapeutics: emerged from stealth with $173M, including a $120M Series B, from 11 investors including founder Scion Life Sciences, OrbiMed and venBio. MAR-101 is a transferrin antibody-siRNA conjugate for sickle cell disease and beta thalassemia, preclinical. — Fierce Biotech
Onward Therapeutics: NT$900M (~US$28M) Series B for its clinical-stage oncology pipeline; syndicate not disclosed. — PR
IPO / FOLLOW-ON
Sellas (SLS): launched a $150M common stock offering (+$22.5M option) after the REGAL readout. J.P. Morgan and TD Cowen are running it; SLS closed $7.47 on 16 Nov. Unpriced at scan. — Preliminary prospectus (SEC)
ACADEMIC CORNER
No relevant academic updates since yesterday’s edition.
Know someone who'd like this?
Forward it along. It takes ten seconds and means a lot to us.
Isomorphic can raise $5B without naming a drug. The FDA can’t name a commissioner.
— The BioBucks Team
